University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
The
Carcinogenic Potency Project

Toluene diisocyanate, commercial grade (2,4 (80%)- and 2,6 (20%)-) (CAS 26471-62-5)
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
pan sub liv mgl pan sub no positive liv vsc 33.7m 250

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. mgl = mammary gland. pan = pancreas. sub = subcutaneous tissue. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Toluene diisocyanate, commercial grade (2,4 (80%)- and 2,6 (20%)-): All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND 2,6 (20%)-) 26471-62-5 6114 M f b6c gav 24m25 TR251 : 0 42.5mg 84.1mg MXB MXB 181.mg / P<.0005 97.9mg 612.mg 2/50 4/50 16/50 abc:hes; liv:hes,hpa; ova:hes; spl:hem; sub:hem. C liv MXA 215.mg / P<.008 103.mg 5.59gm 4/50 5/50 15/50 liv:hpa,hpc. S liv hpa 250.mg / P<.005 c 121.mg 2.38gm 2/50 3/50 12/50 MXA MXA 580.mg * P<.008 c 236.mg 10.7gm 0/50 1/50 5/50 abc:hes; liv:hes; ova:hes; spl:hem; sub:hem. MXA hes 1.20gm * P<.04 362.mg n.s.s. 0/50 0/50 3/50 abc:hes; liv:hes; ova:hes. S TBA MXB 305.mg * P<.5 66.0mg n.s.s. 26/50 31/50 30/50 liv MXB 215.mg / P<.008 103.mg 5.59gm 4/50 5/50 15/50 liv:hpa,hpc,nnd. lun MXB 815.mg * P<.3 282.mg n.s.s. 0/50 3/50 1/50 lun:a/a,a/c. 6115 M m b6c gav 24m25 TR251 : 0 84.9mg 168.mg TBA MXB 253.mg \ P<.3 - 75.0mg n.s.s. 22/50 27/50 (9/50) liv MXB no dre P=1. 371.mg n.s.s. 11/50 12/50 5/50 liv:hpa,hpc,nnd. lun MXB 1.92gm * P<.5 416.mg n.s.s. 2/50 5/50 2/50 lun:a/a,a/c. 6116 M f cd1 inh 24m24 2178 0 .112mg .336mg Loeser;txlt,15,71-81;1983 lun ade es no dre P=1. - .422mg n.s.s. 23/90 20/90 (11/89) lun car es no dre P=1. - 1.22mg n.s.s. 4/90 2/90 (0/89) liv hpc es no dre P=1. - 4.72mg n.s.s. 0/90 1/90 0/89 liv hpa es no dre P=1. - 6.31mg n.s.s. 5/90 0/90 1/89 tba mix es no dre P=1. - .233mg n.s.s. 56/90 50/90 (22/89) tba mal es no dre P=1. - .344mg n.s.s. 30/90 27/90 (10/89) tba ben es no dre P=1. - .389mg n.s.s. 39/90 31/90 (14/89) 6117 M m cd1 inh 24m24 2178 0 93.3ug .280mg lun ade e .300mg \ P<.02 - .136mg n.s.s. 17/90 31/90 (22/90) liv hpc e no dre P=1. - .370mg n.s.s. 24/90 20/90 (12/90) liv hpa e no dre P=1. - .376mg n.s.s. 21/90 18/90 (9/90) lun car e no dre P=1. - 2.45mg n.s.s. 6/90 4/90 4/90 tba mix e 1.63mg \ P<.9 - 96.1ug n.s.s. 64/90 65/90 (43/90) tba mal e no dre P=1. - .186mg n.s.s. 39/90 39/90 (23/90) tba ben e no dre P=1. - 1.08mg n.s.s. 38/90 44/90 29/90 6118 R f f34 gav 25m25 TR251 : 0 42.1mg 83.3mg MXB MXB 25.4mg * P<.0005 14.7mg 57.3mg 19/50 26/50 24/50 liv:nnd; mgl:fba; pni:isa; sub:fbs,fib. C mgl fba 33.4mg * P<.0005 c 18.5mg 87.1mg 15/50 21/50 18/50 liv nnd 92.2mg * P<.0005 c 44.4mg 344.mg 3/50 8/50 8/50 pni MXA 115.mg * P<.0005 51.9mg 383.mg 0/50 7/50 2/50 pni:isa,isc. S pni isa 135.mg * P<.002 c 58.3mg 523.mg 0/50 6/50 2/50 adr phe 143.mg * P<.007 58.4mg 2.25gm 2/50 5/50 4/50 S adr coa 174.mg * P<.007 67.1mg 3.51gm 2/50 3/50 5/50 S sub fib 256.mg * P<.004 87.6mg 1.88gm 0/50 1/50 3/50 S pit cra 77.3mg * P<.03 32.1mg n.s.s. 25/50 15/50 16/50 S pit MXA 86.9mg * P<.05 33.7mg n.s.s. 27/50 15/50 16/50 pit:cra,crc. S sub MXA 206.mg / P<.02 c 73.7mg 43.3gm 2/50 1/50 5/50 sub:fbs,fib. cli adn 260.mg * P<.03 87.3mg n.s.s. 0/50 4/50 0/50 S TBA MXB 25.1mg * P<.0005 13.6mg 82.8mg 45/50 36/50 34/50 liv MXB 92.2mg * P<.0005 44.4mg 344.mg 3/50 8/50 8/50 liv:hpa,hpc,nnd. 6119 R m f34 gav 25m25 TR251 : 0 21.0mg 41.7mg tes MXA 13.6mg * P<.002 6.93mg 71.9mg 48/50 35/50 30/50 tes:ict,itm. S MXB MXB 27.3mg * P<.0005 14.9mg 65.4mg 4/50 8/50 14/50 pan:ana; sub:fbs,fib. C sub MXA 34.1mg * P<.0005 c 18.0mg 88.4mg 3/50 6/50 12/50 sub:fbs,fib. pan ana 51.6mg * P<.0005 c 23.2mg 183.mg 1/50 3/50 7/50 sub fib 56.0mg * P<.0005 25.2mg 239.mg 3/50 3/50 9/50 S pit cra 76.4mg * P<.005 32.2mg 732.mg 3/50 4/50 7/50 S sub fbs 92.4mg * P<.002 36.9mg 421.mg 0/50 3/50 3/50 S pit MXA 83.7mg * P<.02 33.6mg 12.8gm 4/50 4/50 7/50 pit:cra,crc. S sub MXA 103.mg * P<.02 39.2mg n.s.s. 1/50 4/50 3/50 sub:fbs,ost,srn. S pni MXA 201.mg * P<.03 57.7mg n.s.s. 1/50 0/50 4/50 pni:isa,isc. S TBA MXB 18.4mg * P<.002 9.29mg 94.4mg 40/50 24/50 29/50 liv MXB 196.mg * P<.4 42.4mg n.s.s. 7/50 3/50 4/50 liv:hpa,hpc,nnd. 6120 R f cdr inh 25m25 2178 0 26.7ug 80.0ug Loeser;txlt,15,71-81;1983 liv hpc e 8.24mg * P<.3 - 1.34mg n.s.s. 0/104 0/105 1/105 tba mal e 1.09mg * P<.5 - .247mg n.s.s. 21/104 18/105 25/105 tba ben e no dre P=1. - 80.1ug n.s.s. 102/104 94/105 96/105 tba mix e no dre P=1. - 46.5ug n.s.s. 104/104 98/105 101/105 6121 R m cdr inh 26m26 2178 0 18.7ug 56.0ug liv hpc e no dre P=1. - 1.03mg n.s.s. 0/104 1/104 0/104 tba mix e no dre P=1. - 76.3ug n.s.s. 86/104 67/104 81/104 tba ben e no dre P=1. - .103mg n.s.s. 77/104 64/104 71/104 tba mal e 6.18mg * P<1. - .263mg n.s.s. 17/104 14/104 17/104

Mutagenicity in Salmonella: positive

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10